Poly Lactic-Co- Glycolic Acid- (PLGA-) Loaded Nanoformulation of Cisplatin as a Therapeutic Approach for Breast Cancers

被引:13
作者
Alkahtani, Saad [1 ]
Alarifi, Saud [1 ]
Albasher, Gadah [1 ]
Al-Zharani, Mohammed [2 ]
Aljarba, Nada H. [3 ]
Almarzoug, Mohammed H. [1 ]
Alhoshani, Norah M. [1 ]
AL-Johani, Norah S. [1 ]
Alothaid, Hani [4 ]
Alkahtane, Abdullah A. [1 ]
机构
[1] King Saud Univ, Coll Sci, Dept Zool, Riyadh, Saudi Arabia
[2] Imam Muhammad Ibn Saud Islamic Univ, Coll Sci, Dept Biol, Riyadh 11432, Saudi Arabia
[3] Princess Nourah Bint Abdulrahman Univ, Coll Sci, Dept Biol, Riyadh, Saudi Arabia
[4] Al Baha Univ, Fac Appl Med Sci, Dept Basic Sci, Al Baha 65431, Saudi Arabia
关键词
CONTROLLED-RELEASE; NANOPARTICLES; DELIVERY; FUNCTIONALIZATION; DISEASE;
D O I
10.1155/2021/5834418
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Despite recent advancements in cisplatin (cis-diamminedichloroplatinum II) and other platinum-based chemotherapeutic drugs for treating solid tumors, their uses are limited by either in terms of toxicity and/or acquired drug resistance. These side effects have a dangerous problem with higher dose for severe patients. To overcome the low therapeutic ratio of the free drug, a polymeric nanoparticle drug delivery system has been explored promoting delivery of cisplatin to tumors. Recently, the applications of nanoparticles (NPs) have been underlined for encouraging the effects of chemotherapeutic drugs in cancerous cells. The intention of this project is to assess the potential of poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) for enhancing the effects of anticancer drug cisplatin. For the purpose, we have synthesized PLGA-cisplatin nanoparticles for increasing its bioavailability and studied the comparative cytotoxicity of free cisplatin and PLGA-cisplatin against MCF-7 cancer cell lines and HEK-293 normal cell lines. We have also analyzed the hallmarks of PLGA-cisplatin-induced apoptosis. The outcomes of this study may provide the possibility of delivery of anticancer drug to their specific site, which could minimize toxicity and optimize the drug efficacy.
引用
收藏
页数:8
相关论文
共 42 条
[31]   New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA [J].
Reedijk, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3611-3616
[32]   PLGA-Based Nanoparticles in Cancer Treatment [J].
Rezvantalab, Sima ;
Drude, Natascha Ingrid ;
Moraveji, Mostafa Keshavarz ;
Guevener, Nihan ;
Koons, Emily Kate ;
Shi, Yang ;
Lammers, Twan ;
Kiessling, Fabian .
FRONTIERS IN PHARMACOLOGY, 2018, 9
[33]   Exploring the therapeutic potential of nanostructured lipid carrier approaches to tackling the inherent lacuna of chemotherapeutics and herbal drugs against breast cancer [J].
Sartaj, Ali ;
Baboota, Sanjula ;
Ali, Javed .
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2021, 63
[34]   Cisplatin: mode of cytotoxic action and molecular basis of resistance [J].
Siddik, ZH .
ONCOGENE, 2003, 22 (47) :7265-7279
[35]   Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer [J].
Silver, Daniel P. ;
Richardson, Andrea L. ;
Eklund, Aron C. ;
Wang, Zhigang C. ;
Szallasi, Zoltan ;
Li, Qiyuan ;
Juul, Nicolai ;
Leong, Chee-Onn ;
Calogrias, Diana ;
Buraimoh, Ayodele ;
Fatima, Aquila ;
Gelman, Rebecca S. ;
Ryan, Paula D. ;
Tung, Nadine M. ;
De Nicolo, Arcangela ;
Ganesan, Shridar ;
Miron, Alexander ;
Colin, Christian ;
Sgroi, Dennis C. ;
Ellisen, Leif W. ;
Winer, Eric P. ;
Garber, Judy E. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1145-1153
[36]   Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J].
Sorlie, T ;
Perou, CM ;
Tibshirani, R ;
Aas, T ;
Geisler, S ;
Johnsen, H ;
Hastie, T ;
Eisen, MB ;
van de Rijn, M ;
Jeffrey, SS ;
Thorsen, T ;
Quist, H ;
Matese, JC ;
Brown, PO ;
Botstein, D ;
Lonning, PE ;
Borresen-Dale, AL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) :10869-10874
[37]   Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer [J].
ter Brugge, Petra ;
Kristel, Petra ;
van der Burg, Eline ;
Boon, Ute ;
de Maaker, Michiel ;
Lips, Esther ;
Mulder, Lennart ;
de Ruiter, Julian ;
Moutinho, Catia ;
Gevensleben, Heidrun ;
Marangoni, Elisabetta ;
Majewski, Ian ;
Jozwiak, Katarzyna ;
Kloosterman, Wigard ;
van Roosmalen, Markus ;
Duran, Karen ;
Hogervorst, Frans ;
Turner, Nick ;
Esteller, Manel ;
Cuppen, Edwin ;
Wesseling, Jelle ;
Jonkers, Jos .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (11)
[38]   Tumor Heterogeneity in Breast Cancer [J].
Turashvili, Gulisa ;
Brogi, Edi .
FRONTIERS IN MEDICINE, 2017, 4
[39]   Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays [J].
Van Tonder A. ;
Joubert A.M. ;
Cromarty A.D. .
BMC Research Notes, 8 (1)
[40]   Emerging therapeutic modalities of PARP inhibitors in breast cancer [J].
Wang, Xin ;
Shi, Yaqin ;
Huang, Doudou ;
Guan, Xiaoxiang .
CANCER TREATMENT REVIEWS, 2018, 68 :62-68